Nasopharyngeal carcinoma progression is mediated by EBER-triggered inflammation via the RIG-I pathway

Cancer Lett. 2015 May 28;361(1):67-74. doi: 10.1016/j.canlet.2015.02.037. Epub 2015 Feb 23.

Abstract

EBERs (EBER1 and EBER2) are suggested to be involved in cellular transformation and tumor growth. Cytoplasmic pattern recognition receptor-RIG-I, which is characterized by the recognition of viral dsRNAs, could efficiently trigger the downstream pathways of innate immunity. Although some previous reports have shown that EBERs and RIG-I associate with hematological malignancies, the role of EBERs-RIG-I signaling in solid tumors remains to be clarified. Here we demonstrate that EBER mediation of the inflammatory response via RIG-I contributes to NPC development in vitro and in vivo. We first verified that the expression level of RIG-I was associated with EBER transcription in a dose-dependent manner in NPC cells and specimens from NPC patients. Furthermore, pro-inflammatory cytokine transcription and release were sharply reduced after RIG-I knockdown compared with the control shRNA group in the presence of EBERs, accompanied by an attenuation of the NF-κB and MAPK signaling pathways. Consequently, the tumor burden was greatly alleviated in the RIG-I knockdown group in a xenograft model. In addition, macrophage colony-stimulating factor (M-CSF) and monocyte chemoattractant protein (MCP-1), which promote the maturation and attraction of tumor-associated macrophages, were stimulated upon the introduction of EBERs, and this upregulation conceivably led to the tumor-promoting subset transition of the macrophages. Taken together, our results reveal that EBERs could promote NPC progression through RIG-I-mediated cancer-related inflammation.

Keywords: EBV encoded-non-coding RNAs (EBERs); Inflammation; nasopharyngeal carcinoma (NPC); retinoic acid-inducible gene I (RIG-I).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • Carcinoma
  • Cell Differentiation
  • Coculture Techniques
  • Cytokines / genetics
  • Cytokines / metabolism
  • DEAD Box Protein 58
  • DEAD-box RNA Helicases / antagonists & inhibitors
  • DEAD-box RNA Helicases / genetics
  • DEAD-box RNA Helicases / metabolism*
  • Disease Progression
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Immunoprecipitation
  • Inflammation / immunology*
  • Inflammation / metabolism
  • Inflammation / pathology
  • Inflammation Mediators / analysis
  • Interferon Regulatory Factor-3 / genetics
  • Interferon Regulatory Factor-3 / metabolism*
  • Macrophages / immunology
  • Macrophages / metabolism
  • Macrophages / pathology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms / immunology*
  • Nasopharyngeal Neoplasms / metabolism
  • Nasopharyngeal Neoplasms / pathology*
  • RNA, Messenger / genetics
  • RNA, Small Interfering / genetics
  • RNA, Viral / antagonists & inhibitors
  • RNA, Viral / genetics
  • RNA, Viral / metabolism*
  • Real-Time Polymerase Chain Reaction
  • Receptors, Immunologic
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Cells, Cultured
  • Tumor Microenvironment
  • Xenograft Model Antitumor Assays

Substances

  • Cytokines
  • Epstein-Barr virus encoded RNA 1
  • Epstein-Barr virus encoded RNA 2
  • IRF3 protein, human
  • Inflammation Mediators
  • Interferon Regulatory Factor-3
  • NF-kappa B
  • RNA, Messenger
  • RNA, Small Interfering
  • RNA, Viral
  • Receptors, Immunologic
  • RIGI protein, human
  • DEAD Box Protein 58
  • DEAD-box RNA Helicases